; and (5) an overview of the consideration by the FDA of clinical trial methodologies for analgesic drugs, including the enriched enrollment randomized withdrawal methodology, and the benefits and drawbacks associated with different trial methodologies for such drugs, incorporating any public input received under paragraph (1). 116. Consideration of enriched enrollment randomized withdrawal methodology (a) In general Not later than 2 years after the date of enactment of this Act, the Secretary of Health and Human Services (referred to in this section as the Secretary ), acting through the Commissioner of Food and Drugs, shall convene a meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee of the Food and Drug Administration to review the use of the enriched enrollment randomized withdrawal methodology in clinical trials of opioid analgesic drugs and consider and make recommendations regarding the use of alternative clinical study methodologies. In conducting such review, the Secretary shall consider the report issued by the National Academy of Sciences under subsection (c). (b) Presentations If the Secretary allows for formal presentations in support of the use of the enriched enrollment randomized withdrawal methodology at the meeting described in subsection (a), the Secretary shall also allow for equal time at such meeting for presentations that are critical of such methodology. (c) Nas study and report The Secretary shall seek to enter into a contract with the National Academy of Sciences under which the National Academy— (1) conducts a study on the effectiveness of enriched enrollment randomized withdrawal methodology in demonstrating the efficacy of opioid analgesic drugs in treating chronic pain